Philadelphia chromosome‐positive acute lymphoblastic leukemia
Authors:
Abstract
The Philadelphia chromosome (Ph) is the most common cytogenetic abnormality associated with adult acute lymphoblastic leukemia (ALL). Before the advent of tyrosine kinase inhibitors (TKIs), Ph‐positive ALL carried a dismal prognosis and was characterized by a poor response to most chemotherapy combinations, short remission durations, and poor survival rates. Outcomes for patients with Ph‐positive ALL improved substantially with the introduction of TKIs, and the TKI imatinib induced complete remissions in >95% of patients with newly diagnosed Ph‐positive ALL when it was combined with chemotherapy. However, imatinib resistance remains a problem in a substantial proportion of patients with Ph‐positive ALL, and multiple molecular mechanisms that contribute to imatinib resistance have been identified. Second‐generation TKIs (eg, dasatinib and nilotinib) have demonstrated promising efficacy in the treatment of imatinib‐resistant, Ph‐positive ALL. Future strategies for Ph‐positive ALL include novel, molecularly targeted treatment modalities and further evaluations of TKIs in combination with established antileukemic agents. For this article, the authors reviewed past, current, and future treatment approaches for adult and elderly patients with Ph‐positive ALL with a focus on TKIs and combined chemotherapeutic regimens. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 89 references indexed in Scilit:
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemiaBlood, 2008
- P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemiaJournal of Hematology & Oncology, 2008
- Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimenBlood, 2008
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemiaJournal of Clinical Investigation, 2007
- Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemiaBlood, 2006
- Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in miceProceedings of the National Academy of Sciences, 2006
- With a little help from small friends: Enhanced chemotherapeutic effects with imatinibEuropean Journal of Cancer, 2006
- Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemiaAnnals of Hematology, 1992